{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:42:23Z","timestamp":1794271343560,"version":"4.9.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jneuroim.2026.579033","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:01:49Z","timestamp":1784127709000},"page":"579033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Perioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case series"],"prefix":"10.1016","volume":"420","author":[{"given":"Qiurong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jneuroim.2026.579033_bb0005","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579033_bb0010","first-page":"721","article-title":"Chinese guideline for diagnosis and treatment of myasthenia gravis (2025 edition)","volume":"58","author":"Chinese Society of Neuroimmunology","year":"2025","journal-title":"Chin. J. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.579033_bb0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.nmd.2019.07.006","article-title":"Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis","volume":"29","author":"de Meel","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"26","key":"10.1016\/j.jneuroim.2026.579033_bb0020","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.579033_bb0025","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/CON.0000000000001161","article-title":"Diagnosis and Management of Myasthenia Gravis","volume":"28","author":"Hehir","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"10.1016\/j.jneuroim.2026.579033_bb0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.jneuroim.2026.579033_bb0035","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jneuroim.2026.579033_bb0040","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579033_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","article-title":"Thymus and autoimmunity","volume":"43","author":"Marx","year":"2021","journal-title":"Semin. Immunopathol."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.579033_bb0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579033_bb0055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/B978-0-12-823912-4.00026-8","article-title":"Myasthenia gravis-Pathophysiology, diagnosis, and treatment","volume":"200","author":"Tannemaat","year":"2024","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579033_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2024.109241","article-title":"Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: a case report","volume":"115","author":"Wang","year":"2024","journal-title":"Int. J. Surg. Case Rep."},{"issue":"8","key":"10.1016\/j.jneuroim.2026.579033_bb0065","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jtho.2025.04.014","article-title":"Perioperative safety and efficacy of Efgartigimod for Thymoma-associated myasthenia gravis: a prospective, multicenter, phase II clinical trial","volume":"20","author":"Wang","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.579033_bb0070","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00415-025-13367-8","article-title":"Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study","volume":"272","author":"Zhu","year":"2025","journal-title":"J. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:25:14Z","timestamp":1788873914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":14,"alternative-id":["S0165572826001827"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579033","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"579033"}}